Eisai, Biogen (BIIB) Report Phase II Study Of Elenbecestat Demonstrated Safety And Tolerability In MCI And Mild To Moderate AD At 18-Months
Tweet Send to a Friend
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced today that elenbecestat was generally safe and well tolerated in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
